Literature DB >> 34246868

Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience.

Martin K Madsen1, Dea S Stenbæk2, Albin Arvidsson2, Sophia Armand2, Maja R Marstrand-Joergensen2, Sys S Johansen3, Kristian Linnet3, Brice Ozenne4, Gitte M Knudsen1, Patrick M Fisher5.   

Abstract

The emerging novel therapeutic psilocybin produces psychedelic effects via engagement of cerebral serotonergic targets by psilocin (active metabolite). The serotonin 2A receptor critically mediates these effects by altering distributed neural processes that manifest as increased entropy, reduced functional connectivity (FC) within discrete brain networks (i.e., reduced integrity) and increased FC between networks (i.e., reduced segregation). Reduced integrity of the default mode network (DMN) is proposed to play a particularly prominent role in psychedelic phenomenology, including perceived ego-dissolution. Here, we investigate the effects of a psychoactive peroral dose of psilocybin (0.2-0.3 mg/kg) on plasma psilocin level (PPL), subjective drug intensity (SDI) and their association in fifteen healthy individuals. We further evaluate associations between these measures and resting-state FC, measured with functional magnetic resonance imaging, acquired over the course of five hours after psilocybin administration. We show that PPL and SDI correlate negatively with measures of network integrity (including DMN) and segregation, both spatially constrained and unconstrained. We also find that the executive control network and dorsal attention network desegregate, increasing connectivity with other networks and throughout the brain as a function of PPL and SDI. These findings provide direct evidence that psilocin critically shapes the time course and magnitude of changes in the cerebral functional architecture and subjective experience following psilocybin administration. Our findings provide novel insight into the neurobiological mechanisms underlying profound perceptual experiences evoked by this emerging transnosological therapeutic and implicate the expression of network integrity and segregation in the psychedelic experience and consciousness.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Experience; Functional connectivity; Psilocin; Psilocybin; Psychedelic; fMRI

Mesh:

Substances:

Year:  2021        PMID: 34246868     DOI: 10.1016/j.euroneuro.2021.06.001

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  5 in total

Review 1.  Sustained effects of single doses of classical psychedelics in humans.

Authors:  Gitte M Knudsen
Journal:  Neuropsychopharmacology       Date:  2022-06-21       Impact factor: 7.853

Review 2.  Schizophrenia and psychedelic state: Dysconnection versus hyper-connection. A perspective on two different models of psychosis stemming from dysfunctional integration processes.

Authors:  Jacopo Sapienza; Marta Bosia; Marco Spangaro; Francesca Martini; Giulia Agostoni; Federica Cuoco; Federica Cocchi; Roberto Cavallaro
Journal:  Mol Psychiatry       Date:  2022-08-05       Impact factor: 13.437

3.  Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report.

Authors:  Drummond E-Wen McCulloch; Maria Zofia Grzywacz; Martin Korsbak Madsen; Peter Steen Jensen; Brice Ozenne; Sophia Armand; Gitte Moos Knudsen; Patrick MacDonald Fisher; Dea Siggaard Stenbæk
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

4.  How Psychedelic-Assisted Treatment Works in the Bayesian Brain.

Authors:  Daniel Villiger
Journal:  Front Psychiatry       Date:  2022-03-08       Impact factor: 4.157

5.  Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel-Mediated Cardiotoxicity.

Authors:  Benjamin Hackl; Hannes Todt; Helmut Kubista; Karlheinz Hilber; Xaver Koenig
Journal:  Int J Neuropsychopharmacol       Date:  2022-04-19       Impact factor: 5.678

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.